


Amendments to the Specification:

Please insert the following as the first paragraph beneath the title on page 1:

This application is a divisional of U.S. Patent Application No.10/111,322, filed April 22, 2002, which is 371 of PCT Patent Application No. PCT/EP00/10528; filed October 25, 2000, which in their entirety are herein incorporated by reference.

Please insert the following Abstract as the last page of the application. A copy is attached on a separate page.

Compounds of formula (I)



and pharmaceutically-acceptable and pharmaceutically-acceptable and -cleavable esters thereof and acid addition salts thereof, wherein the symbols are as defined are MAP kinase inhibitors, useful pharmaceutically for treating TNF α and IL-1 mediated diseases such as rheumatoid arthritis and diseases of bone metabolism, e.g. osteoporosis.